Write in a clean editor, then format for Amyotrophic Lateral Sclerosis in one click — DocuGuru applies the official Taylor & Francis template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Amyotrophic Lateral Sclerosis is a peer-reviewed journal published by Taylor & Francis, covering Amyotrophic Lateral Sclerosis Research, Neurogenetic and Muscular Disorders Research, Parkinson's Disease Mechanisms and Treatments.
| Publisher | Taylor & Francis |
|---|---|
| Reference style | Author–year (Chicago, T&F) Author–year — (Smith, 2023) in the text Smith, Ada, Ben Jones, and Cara Lee. 2023. "A Representative Article Title." Amyotrophic Lateral Sclerosis 12 (3): 45–58.
Formats any DOI in Amyotrophic Lateral Sclerosis style. No sign-up. |
| Publishes research in | Amyotrophic Lateral Sclerosis Research Neurogenetic and Muscular Disorders Research Parkinson's Disease Mechanisms and Treatments Genetic Neurodegenerative Diseases Neurological diseases and metabolism |
| ISSN | 1471-180X |
| h-index | 84 |
| i10-index | 526 |
| Total citations | 29,138 |
| Top institutions publishing here | Massachusetts General Hospital |
| Journal website | www.tandfonline.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
We have performed a systematic review to summarize current knowledge concerning factors related to survival in ALS and to evaluate the implications of these data for clinical trials design. The median survival time from onset to death ranges from 20 to 48 months, but 10-20% of ALS patients have a survival longer than 10 years.…
Amyotrophic lateral sclerosis (ALS) is increasingly recognized to be a multisystem disorder which includes both clinical and neuropathological features of a frontotemporal lobar degeneration (FTLD). In order to provide a common framework within which to discuss the characteristics of the cognitive and behavioural syndromes of ALS, and with which to conduct clinical and neuropathological research,…
Identification of SOD1 as the mutated protein in a significant subset of familial amyotrophic lateral sclerosis (FALS) cases has led to the generation of transgenic rodent models of autosomal dominant SOD1 FALS. Mice carrying 23 copies of the human SOD1(G93A) transgene are considered the standard model for FALS and ALS therapeutic studies. To date, there…
Our objective was to develop and validate a new brain-computer interface (BCI) system suitable for long-term independent home use by people with severe motor disabilities. The BCI was used by a 51-year-old male with ALS who could no longer use conventional assistive devices. Caregivers learned to place the electrode cap, add electrode gel, and turn…
The development of therapeutics for ALS/MND is largely based on work in experimental animals carrying human SOD mutations. However, translation of apparent therapeutic successes from in vivo to the human disease has proven difficult and a considerable amount of financial resources has been apparently wasted. Standard operating procedures (SOPs) for preclinical animal research in ALS/MND…
